| Hans-Günter Meyer-Thompson | HIV
Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial
Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial
Pantaleo, Giuseppe et al.
The Lancet HIV, Volume 6, Issue 11, e737 - e749
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(19)30262-0/fulltext